3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1/2
1
Status
Withdrawn
1
Unknown
1
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
Sarcoma
5
Gastrointestinal
4
Thoracic
2
Breast
2
Other solid neoplasm
1
NET
1
Head & Neck
1
Genitourinary
1
Endocrine
1
Conditions
Breast Neoplasms
10163
Triple Negative Breast Neoplasms
1042
Neoplasms
572
Ovarian Neoplasms
560
Neoplasm Metastasis
513
Colorectal Neoplasms
467
Carcinoma, Non-Small-Cell Lung
465
Prostatic Neoplasms
439
Lung Neoplasms
432
Pancreatic Neoplasms
312
Melanoma
299
Stomach Neoplasms
294
Breast Neoplasms, Male
257
Motor Activity
252
Colonic Neoplasms
238
Uterine Cervical Neoplasms
225
Endometrial Neoplasms
221
Head and Neck Neoplasms
217
Carcinoma, Intraductal, Noninfiltrating
217
Carcinoma, Renal Cell
191
Squamous Cell Carcinoma of Head and Neck
179
Sarcoma
175
Urinary Bladder Neoplasms
159
Brain Neoplasms
155
Esophageal Neoplasms
154
Breast Carcinoma In Situ
154
Lymphedema
148
Fatigue
136
Carcinoma, Ovarian Epithelial
134
Small Cell Lung Carcinoma
128
Interventions
regorafenib
1
brigimadlin
1
Clinical Trials, Phase II as Topic
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Interventional
×
Tertiary Lymphoid Structures
×
Breast
×
Clear all
NCT06084689
2025-09-02
EMPIRE
Institut Bergonié
Phase 2
Withdrawn
NCT03475953
2023-03-03
REGOMUNE
Institut Bergonié
Phase 1/2
Unknown
747 enrolled